Back to Results

Autolus Therapeutics Ltd (AUTL)

Autolus Therapeutics Ltd is a NASDAQ-listed depositary receipt tied to Autolus Therapeutics plc, a clinical-stage biopharmaceutical company focused on T cell therapies for cancer and autoimmune diseases. The company’s pipeline includes several investigational programs in development in the United Kingdom and other international markets. These include obecabtagene autoleucel (AUTO1) for adult ALL, AUTO1/22 for pediatric relapsed or refractory ALL, AUTO4 for peripheral T-cell lymphoma, AUTO6NG for neuroblastoma, and AUTO8 for multiple myeloma. Autolus is also advancing AUTO5, a preclinical TRBC2 program for peripheral T-cell lymphoma. The issuer was incorporated in 2014 and is headquartered in London, United Kingdom.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-AUTL
$2.20
8.2% Upside
Fair
$8.72
329.8% Upside
Bargain
Fair
0.0%
October 29, 2026
7.2x
4.6x
540.3 M
706.5 M
41.6%
38.7%
-6.7
83.1%
Valuation • Fair Value

Autolus Therapeutics Ltd (NASDAQ-AUTL) Fair Value by Valuation Model

Review the available estimates for Autolus Therapeutics Ltd (NASDAQ-AUTL), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$2.20

Estimated upside of 8.2% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$2.31

Discounted cash flow valuation reference.

Comps Fair Value

$2.10

Comparable-company valuation reference.

Analyst Price Target

$8.72

Analysts imply upside of 329.8%.

How to read these valuation models

Use the 5 available valuation references for Autolus Therapeutics Ltd (NASDAQ-AUTL) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Autolus Therapeutics Ltd (NASDAQ-AUTL)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

117.4 M

Current operating scale indicator.

Revenue Forecast

149 M

Forward revenue estimate.

EBITDA

-236.6 M

Current operating profitability reference.

EBITDA Forecast

-194.4 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Autolus Therapeutics Ltd (NASDAQ-AUTL) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Autolus Therapeutics Ltd (NASDAQ-AUTL)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

3.52

Higher caution zone on this screen.

Altman Z-Score

-6.7

Lower score that deserves closer risk review.

FCF / Net Income

83.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Autolus Therapeutics Ltd (NASDAQ-AUTL). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Autolus Therapeutics Ltd (NASDAQ-AUTL)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

October 29, 2026

Days to Earnings

37

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Autolus Therapeutics Ltd (NASDAQ-AUTL), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Autolus Therapeutics Ltd (NASDAQ-AUTL) Stock Forecast & Technical Outlook

Review Autolus Therapeutics Ltd (NASDAQ-AUTL) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Buy

The 15-minute technical read for Autolus Therapeutics Ltd (NASDAQ-AUTL) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Autolus Therapeutics Ltd (NASDAQ-AUTL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Autolus Therapeutics Ltd (NASDAQ-AUTL) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Autolus Therapeutics Ltd (NASDAQ-AUTL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Buy

The monthly technical read for Autolus Therapeutics Ltd (NASDAQ-AUTL) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Autolus Therapeutics Ltd (NASDAQ-AUTL)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Autolus Therapeutics Ltd (NASDAQ-AUTL) has a Strong Buy consensus, with 8 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 8
Hold 0
Sell 0
FAQ • Fast Investor Answers

Autolus Therapeutics Ltd (NASDAQ-AUTL) Stock FAQ

Data-supported answers about Autolus Therapeutics Ltd (NASDAQ-AUTL), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$2.20
Estimated upside 8.2%
Valuation Rating
Undervalued
Estimated upside of 8.2%
Analyst Target
$8.72
Implied upside 329.8%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Autolus Therapeutics Ltd (NASDAQ-AUTL) is $2.20. This implies an estimated upside of 8.2% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 8.2% versus the current market price.

The available analyst price target for Autolus Therapeutics Ltd (NASDAQ-AUTL) is $8.72. The analyst target implies estimated upside of 329.8%.

The current financial health read for Autolus Therapeutics Ltd (NASDAQ-AUTL) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Autolus Therapeutics Ltd (NASDAQ-AUTL) is October 29, 2026.

The latest available data indicates no current dividend yield for Autolus Therapeutics Ltd (NASDAQ-AUTL).

The current market capitalization listed for Autolus Therapeutics Ltd is 540.3 M.

The current enterprise value listed for Autolus Therapeutics Ltd is 706.5 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Autolus Therapeutics Ltd is NASDAQ-AUTL, and the stock is listed on NASDAQ.

Autolus Therapeutics Ltd (NASDAQ-AUTL) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Autolus Therapeutics Ltd is 41.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Autolus Therapeutics Ltd is 38.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B